

FULL TEXT LINKS

begell

Review Int J Med Mushrooms. 2023;25(5):1-15. doi: 10.1615/IntJMedMushrooms.2023048109.

The Lingzhi or Reishi Medicinal Mushroom Ganoderma lucidum (Agaricomycetes) Can Combat Cytokine Storm and Other COVID-19 Related Pathologies: A Review

Adekunle Babajide Rowaiye ¹, Akwoba Joseph Ogugua ², Doofan Bur ¹, Timipanipiri Wood ¹, Zainab Labbo ¹, Chimaobi Chukwu ¹, Femi Johnson Afolabi ¹, Ezinne Janefrances Nwonu ¹, Tarimoboere Agbalalah ³

Affiliations PMID: 37183915 DOI: 10.1615/IntJMedMushrooms.2023048109

Abstract

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is characterized by acute respiratory distress syndrome (ARDS) facilitated by cytokine storm and other risk factors that increase susceptibility and complications leading to death. Emerging as a major global public health challenge, the disease has claimed more than 6 million lives and caused catastrophic global economic disruptions. However, there are concerns about the safety as well as the efficacy of drugs and vaccines presently used to control the pandemic, therefore necessitating intense global search for safe natural products that can effectively and safely combat it. This work reviews studies on lingzhi or reishi medicinal mushroom, Ganoderma lucidum and its properties that may potentially combat SARS-CoV-2 infection and the co-morbidities. Available evidence suggests that medicinal properties of the Ganoderma mushroom can combat the complications of SARS-CoV-2 infection and the co-morbidities that can aggravate the severity of the disease. Preclinical and clinical evaluation to establish dose, efficacy, and potential toxicity and possible use in the management of COVID-19 is recommended.

PubMed Disclaimer

Related information

MedGen

LinkOut - more resources

Full Text Sources BegellHouse Publisher, Inc.

Medical MedlinePlus Health Information

Miscellaneous NCI CPTAC Assay Portal